Profile
ABVC NVO VRTX REGN SGEN ARGX
Company Name ABVC BioPharma, Inc. Novo Nordisk A/S Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Seagen Inc. argenx SE
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $7.36M $456.40B $116.20B $80.34B $43.15B $35.73B
Employees 0.02K 71.88K 5.40K 14.17K 3.26K 1.15K
CEO Dr. Uttam Yashwant Patil Ph.D. Mr. Lars Fruergaard Jorgensen Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. David R. Epstein B.Sc., M.B.A. Mr. Timothy Van Hauwermeiren EMBA, M.Sc.
Ratings
ABVC NVO VRTX REGN SGEN ARGX
Quant Rating Score 2 3 3 4 3 1
Quant Rating Sell Neutral Neutral Buy Neutral Strong Sell
Trading
ABVC NVO VRTX REGN SGEN ARGX
Last Close $0.5674 $105.27 $451.23 $743.35 $228.74 $591.82
High 52 $1.93 $146.91 $516.74 $1201.76 $228.74 $602.47
Low 52 $0.47 $101.74 $392.81 $743.35 $228.74 $356.01
Price vs. 52 Week High -70.6 % -28.34 % -12.68 % -38.14 % 0 % -1.77 %
Price vs. 52 Week Low 20.72 % 3.47 % 14.87 % 0 % 0 % 66.24 %
Total Return
ABVC NVO VRTX REGN SGEN ARGX
1 Month Return 5.07 % -10.28 % -5.62 % -23.25 % 0 % 5.6 %
3 Month Return -22.35 % -22 % -7.18 % -37.29 % 0 % 12.62 %
6 Month Return -47.46 % -22.11 % 2.09 % -25.21 % 0 % 65.93 %
9 Month Return -52.32 % -12.95 % 7.53 % -21.99 % 0 % 47.97 %
YTD Return -51.09 % 1.76 % 10.9 % -15.36 % 0 % 55.57 %
1 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ABVC NVO VRTX REGN SGEN ARGX
Dividend Yield Percentage (TTM) - 1.42 % - - - -
Dividend Paid and Capex Coverage Ration (TTM) -89.92 % 1.24 % -2.62 % 4.88 % -2.27 % -2.22 %
Dividend Per Share (TTM) - 0.21 % - - - -
Payout Ratio (TTM) - 46.6 % - - - -
Growth
ABVC NVO VRTX REGN SGEN ARGX
Asset Growth 51.63 % 30.35 % 25.23 % 13.23 % -1.21 % 44.93 %
Gross Profit Growth -126.07 % 32.32 % 9.25 % 6.49 % 22.93 % 190.7 %
Revenue Growth -84.28 % 31.26 % 10.17 % 7.76 % 24.65 % 198.56 %
Revenue 3 Year -85.65 % 90.51 % 59.87 % 55.67 % 91.84 % 2074.24 %
Revenue 5 Year 486.65 % 124.2 % 218.58 % 110.3 % 215.48 % 3040.37 %
Revenue 10 Year - 66.11 % 608.27 % 549.62 % 494.04 % 9013.37 %
EBIT Growth 45.64 % 37.11 % -12.94 % -14.6 % 10.13 % 40.94 %
Net Income Growth 35.54 % 50.71 % 8.96 % -8.87 % 9.51 % 58.42 %
Net Income 3 Yeari Growth Per Share 54.86 % 106.79 % 34.59 % 13.48 % -764.83 % 63.97 %
Net Income 5 Yeari Growth Per Share 31.36 % 133.86 % 70.33 % 74.02 % -276.93 % -143.56 %
Net Income 10 Yeari Growth Per Share -558.32 % 98.61 % 809.6 % 871.12 % -624.16 % -857.4 %
Operating Income Growth 45.64 % 37.11 % -12.94 % -14.6 % 10.13 % 40.94 %
Operating Cash Flow Growth (CFG) 45.09 % 38.06 % -14.35 % -8.39 % 9.07 % 51.28 %
Operating 3 Year CFG 59.52 % 118.29 % 9.63 % 76.95 % -148.34 % 21.62 %
Operating 5 Year CFG -72.59 % 163.51 % 174.78 % 125.17 % -195.86 % -329.48 %
Operating 10 Year CFG -115.24 % 150.92 % 6084.35 % 713.56 % -2622.09 % -1280.79 %
EPS Growth 52.82 % 52.28 % 8.33 % -8.54 % 10.81 % 60.46 %
EPS Diluted Growth 52.82 % 52.37 % 8.35 % -9.03 % 10.81 % 60.46 %
Book Value Per Share 73.36 % 29 % 25.58 % 15.03 % -9.83 % 38.53 %
Share Holder 3 Year Equity Growth Per Share 16.91 % 75.22 % 104.06 % 137.56 % 33.92 % 93.95 %
Share Holder 5 Year Equity Growth Per Share 141.16 % 121.9 % 291.14 % 219.1 % 220.81 % 318.67 %
Share Holder 10 Year Equity Growth Per Share -98.73 % 49.62 % 1030.79 % 1286.9 % 691.19 % 3655.65 %
Dividend Per Share Growth - 26.89 % - - - -
Dividend 3 Year Growth Per Share - 64.4 % - - - -
Dividend 5 Year Growth Per Share - 80.03 % - - - -
Dividend 10 Year Growth Per Share - 95.44 % - - - -
Debt Growth -19.76 % 4.74 % 44.1 % 0.06 % -23.28 % 60.95 %
Free Cash Flow Growth 45.68 % 9.17 % -16.47 % -17.11 % 3.67 % 51.98 %
Updated On 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2022 31 Dec 2023
Profitability
ABVC NVO VRTX REGN SGEN ARGX
Gross Profit Margin TTM 70.8 % 84.66 % 86.1 % 83.54 % 72.37 % 86.82 %
Return on Assets TTM -57 % 23.83 % -2.16 % 12.43 % -11.76 % -2.13 %
Return on Equity TTM -98.4 % 86.4 % -2.88 % 16.85 % -16.53 % -2.75 %
Return on Capital Employed TTM -77.73 % 62.9 % -1.72 % 11.85 % -16.87 % -8.98 %
Net Income Per EBT TTM 95.26 % 79.43 % -184.82 % 93.66 % 100.55 % 167.72 %
EBT Per Ebit TTM 136.64 % 100.27 % -82.68 % 124.1 % 94.01 % 15.76 %
EBIT Per Revenue TTM -1242.22 % 43.96 % -2.96 % 28.92 % -36.09 % -17.08 %
Cash Flow To Debt Ratio TTM -104.83 % 207.5 % - 214.08 % -185.98 % -
Receivables Turnover TTM 42.51 3.4 6.06 2.27 1.98 3.45
Payables Turnover TTM - 1.72 3.73 4.58 1.54 1.06
Inventory Turnover TTM -1.46 1.09 1.37 0.76 0.65 0.91
Fixed Asset Turnover TTM 6.04 % 225.8 % 422.11 % 311.93 % 256.83 % 6116.64 %
Asset Turnover TTM 3.52 % 68.08 % 47.71 % 36.98 % 34.46 % 47.09 %
Operating Cash Flow Per Share TTM -0.15 26.54 -3.27 39.29 -1.12 -2.42
Free Cash Flow Per Share TTM -0.15 15.05 -4.51 31.25 -1.62 -3.52
Cash Per Share TTM 1.68 % 1681.3 % 2528.88 % 9062.44 % 657.5 % 5163.05 %
Operating Cash Flow Sales Ratio TTM -373.95 % 43.69 % -7.94 % 30.67 % -16.85 % -6.44 %
Free Cash Flow Operating Cash Flow Ratio TTM 98.89 % 56.7 % 138.12 % 79.52 % 144.14 % 145.12 %
Cash Flow Coverage Ratios TTM -104.83 % 207.5 % - 214.08 % -185.98 % -
Price To Free Cash Flows Ratio TTM -3.91 48.27 -99.85 23.78 -141.85 -169.15
Price To Operating Cash Flows Ratio TTM -3.69 28.12 -138.16 18.92 -203.89 -244.33
Price Cash Flow Ratio TTM -3.69 28.12 -138.16 18.92 -203.89 -244.33
Income Statement (TTM)
ABVC NVO VRTX REGN SGEN ARGX
Revenue $0B $232.26B $9.87B $13.12B $1.96B $1.23B
Gross Profit $-0B $196.5B $8.61B $11.3B $1.55B $1.11B
Gross Profit Ratio -98.15% 84.6% 87.21% 86.16% 79.1% 90.39%
EBITDA $-0.01B $114.63B $4.61B $4.65B $-0.62B $-0.22B
Net Income $-0.01B $83.68B $3.62B $3.95B $-0.61B $-0.3B
EPS Diluted -2.43 18.62 13.89 34.77 -3.3 -5.16
Balance Sheet (MRQ)
ABVC NVO VRTX REGN SGEN ARGX
Long Term Debt $0B $20.53B $1.45B $2.7B $0.04B $0.02B
Total Liabilities $0.01B $207.93B $5.15B $7.11B $0.87B $0.44B
Total Equity $0.01B $106.56B $17.58B $25.97B $2.8B $4.1B
Total Investments $0B $17.5B $3.45B $13.51B $1.42B $1.18B
Total Debt $0B $27.01B $0.81B $2.7B $0.04B $0.02B
Total Assets $0.01B $314.49B $22.73B $33.08B $3.67B $4.54B
Cash Flow Statement (TTM)
ABVC NVO VRTX REGN SGEN ARGX
Net Income $-0.01B $83.68B $3.62B $3.95B $-0.61B $-0.43B
Inventory $0B $-7.42B $-0.32B $-0.27B $-0.23B $-0.08B
Dividends Paid $0B $-31.77B $0B $0B $0B $0B
Operating Cash Flow $-0B $108.91B $3.54B $4.59B $-0.45B $-0.42B
Capital Expenditure $-0B $-38.9B $-0.26B $-0.93B $-0.08B $-0.04B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.34
ABCL AbCellera Biologics Inc. 2.725
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.92
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 2.28
ABSI Absci Corporation 2.645
ABUS Arbutus Biopharma Corporation 3.495
ABVX Abivax SA American Depositary Shares 8.69
ACAD ACADIA Pharmaceuticals Inc. 16.145
ACER Acer Therapeutics Inc. 0.9
ACET Adicet Bio, Inc. 0.9492
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.055
ACHV Achieve Life Sciences, Inc. 4.33
ACIU AC Immune SA 3.2599
ACLX Arcellx, Inc. 88.79
ACRV Acrivon Therapeutics, Inc. Common Stock 6.5
ACST Acasti Pharma Inc. 3.37
ACXP Acurx Pharmaceuticals, Inc. 1.3001
ETFs With Exposure to ABVC
Ticker ETF Name Weight Percentage Price
VTI Vanguard Total Stock Market Index Fund 0 294.3
VXF Vanguard Extended Market Index Fund 0 200.195
IWC iShares Micro-Cap ETF 0 132.56
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 149.17
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 149.17
VEMPX Vanguard Extended Market Index InstlPlus 0 368.12
Unlock